Trillium Therapeutics (TRIL) Investor Presentation - Slideshow. TORONTO, April 08, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,. Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the... | …
Cambridge Office. Presentations. Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). Our lead programs are directed against CD47, an immune checkpoint that functions as a “do not eat” signal. View this Presentation (PDF) Corporate Presentation April 2020.
About Trillium Therapeutics Trillium is … 29, 2020 at 5:24 p.m. The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). Under carefully defined conditions, fluorination can improve potency, stability and safety, and other critical drug attributes. Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
We employ biologic and small molecule-based approaches that enhance the ability of the patient’s own immune system to detect and destroy cancer cells. About Trillium Therapeutics. Our lead CD47 blocker, TTI-621, is a potent, dual function molecule that is designed to inhibit CD47 on the tumor cell and simultaneously deliver an activating signal to the immune system, whereas most competitor CD47 blockers require a second drug for full activation. ET on Seeking Alpha
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. Trillium is employing our medicinal chemistry expertise which includes a proprietary platform that uses fluorine-based chemistry to yield new chemical entities. Corporate Presentation January 2017 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future... | January 25, 2017 Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
About Trillium Therapeutics. 29, 2020 at 5:24 p.m. Trillium is developing biologics and small molecules to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program Published: May 13, … Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. About Trillium Therapeutics. Trillium Therapeutics (TRIL) Investor Presentation - Slideshow Trillium Therapeutics (TRIL) Investor Presentation - Slideshow May. This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. PowerPoint Presentation Q1/2016 This presentation may contain forward-looking statements, which reflect... | January 12, 2016 Trillium Therapeutics (TRIL) Investor Presentation - Slideshow Trillium Therapeutics (TRIL) Investor Presentation - Slideshow May. ET on Seeking Alpha
We employ biologic and small molecule-based approaches that enhance the ability of the patient’s own immune system to detect and destroy cancer cells. The results of the director elections were as follows: A live audio webcast of the H.C. Wainwright 21 st Annual Global Investment Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com. Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the... | …
Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program Published: May 13, … View this Presentation (PDF) Corporate Presentation January 2020. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented new pharmacology data from its ongoing Phase 1 a/b... | February 24, 2017 Trillium Therapeutics Inc. CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL) (the "Corporation"), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting") held on June 30, 2020. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or